We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: semaglutide
MedXY News
EnglishTag

semaglutide

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Semaglutide Drives Vascular Regeneration: The SEMA-VR CardioLink-15 Trial Reveals a Shift in Progenitor Cell Flux
CardiologyASCVDGLP-1 receptor agonists

Semaglutide Drives Vascular Regeneration: The SEMA-VR CardioLink-15 Trial Reveals a Shift in Progenitor Cell Flux

By MedXY|Mar 9, 2026

The SEMA-VR CardioLink-15 trial demonstrates that semaglutide shifts bone marrow-derived progenitor cells toward an anti-inflammatory, pro-regenerative profile, potentially enhancing endogenous vessel repair in high-risk cardiovascular pati

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial
Diabetes & Endocrinologycardiometabolic riskGLP-1 receptor agonists
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

By MedXY|Feb 11, 2026

A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentia

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success
Cardiologycardiovascular diseaseCost-Effectiveness

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

By MedXY|Feb 5, 2026

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic

Semaglutide Delivers Consistent Functional Gains in Peripheral Artery Disease Regardless of Sex: Evidence from the STRIDE Trial
CardiologyPeripheral Artery Diseasesemaglutide

Semaglutide Delivers Consistent Functional Gains in Peripheral Artery Disease Regardless of Sex: Evidence from the STRIDE Trial

By MedXY|Jan 17, 2026

A post hoc analysis of the STRIDE trial reveals that once-weekly semaglutide 1.0 mg significantly improves walking distance and quality of life in both men and women with type 2 diabetes and peripheral artery disease, despite notable differ

Weekly Semaglutide 2.4 mg Delivers 16% Weight Loss in Asian Adults with BMI ≥25: Results from the STEP 11 Phase 3 Trial
Diabetes & Endocrinologyobesitysemaglutide

Weekly Semaglutide 2.4 mg Delivers 16% Weight Loss in Asian Adults with BMI ≥25: Results from the STEP 11 Phase 3 Trial

By MedXY|Jan 15, 2026

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight by 16% in Asian adults with obesity (BMI ≥25 kg/m2), providing robust evidence for population-specific clinical guidelines and reimbursement

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models
Cardiologycardiovascular outcomesGLP-1 receptor agonists

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

By MedXY|Jan 4, 2026

A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight re

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Cardiologycardiovascular diseasehospitalization

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

By MedXY|Dec 23, 2025

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesit

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit
Cardiologycardiovascular outcomesobesity

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

By MedXY|Nov 11, 2025

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence
Diabetes & EndocrinologyGLP-1 receptor agonistsliraglutide

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY|Oct 31, 2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT
Diabetes & Endocrinologyobesityprediabetes

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY|Oct 22, 2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychi

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial
Diabetes & Endocrinologyclinical trialobesity

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY|Oct 18, 2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis
Diabetes & Endocrinologybiomarkersliver fibrosis

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 9, 2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide
Clinical Updatesmetforminobesity

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

By MedXY|Oct 7, 2025

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity
Diabetes & Endocrinologycagrilintideobesity

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY|Oct 6, 2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerabi

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial
Diabetes & EndocrinologyAsian PopulationBMI

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY|Oct 6, 2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial
Clinical UpdatesPeripheral Artery Diseasesemaglutide

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

By MedXY|Oct 6, 2025

The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence
Cardiologyheart failure with preserved ejection fractionsemaglutide

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

By MedXY|Oct 5, 2025

Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity
Diabetes & EndocrinologycagrilintideCagriSema

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY|Oct 5, 2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option fo

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial
Cardiologycardiovascular outcomeschronic kidney disease

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY|Oct 3, 2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial
Clinical Updatesclinical trialobesity

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY|Oct 1, 2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities